In a research note released yesterday, H.C.
In a research report issued today, Roth Capital analyst Scott Henry assigned a Buy rating on Catalyst Pharmaceutical (NASDAQ:CPRX) with a $5.00 price …
In a research report issued today, Roth Capital analyst Scott Henry maintained a Buy rating on Catalyst Pharmaceutical (NASDAQ:CPRX) with a $3.50 price target, …
In a report published today, Roth Capital analyst Scott Henry maintained a Buy rating on shares of Catalyst Pharmaceutical (CPRX) with a $3.50 price target, following the company’s second-quarter results.
Catalyst Pharmaceutical (CPRX) announced Monday that the last patient has completed the blinded portion of the ongoing pivotal phase 3 study of Firdapse (amifampridine phosphate) …
